Help appealing denials for this oral PDE4 inhibitor for lung fibrosis.

Appeal Your Jascayd Denial

Get access to this new treatment option for idiopathic pulmonary fibrosis.

Understanding Your Jascayd (nerandomilast) Denial

Jascayd (nerandomilast) is a PDE4 inhibitor approved for the treatment of idiopathic pulmonary fibrosis (IPF) in adults. IPF is a serious, progressive lung disease with limited treatment options. If your pulmonologist prescribed Jascayd, you have strong grounds for appeal.

Common Reasons for Denial

! Prior authorization required
! IPF diagnosis not adequately documented
! Must try nintedanib or pirfenidone first
! Step therapy requirement not met
! High-cost specialty medication
! Pulmonary function tests not provided

How We Help

We help you document your IPF diagnosis (including high-resolution CT findings), pulmonary function tests, prior treatments, and why Jascayd is the appropriate choice for your condition.

Start your Jascayd appeal — it takes about 3 minutes.

Some Types of Evidence We Can Use For Supporting Your Appeal

✓ Nerandomilast is a phosphodiesterase 4 (PDE4) inhibitor that reduces inflammation and fibrotic processes in the lungs.

✓ Clinical trials demonstrated slowing of lung function decline in patients with idiopathic pulmonary fibrosis.

✓ IPF is a progressive, fatal disease with median survival of 3-5 years from diagnosis without treatment.

✓ Additional treatment options are needed for patients who cannot tolerate or do not respond to existing antifibrotic therapies.

Patient Assistance & Copay Programs

These programs may help reduce your costs while you appeal:

CareConnect4Me (Boehringer Ingelheim)

Patient support program offering copay assistance, insurance navigation, and help with access. Boehringer Cares Patient Assistance Program available for eligible uninsured patients. Call 1-800-542-6257.

Eligibility requirements and program terms may change. Please verify current details directly with each organization.

Patient Advocacy & Support Organizations

These organizations provide education, support, and advocacy for patients:

Pulmonary Fibrosis Foundation

Largest nonprofit dedicated to pulmonary fibrosis research and patient support. Help Center: 844.TalkPFF.

Frequently Asked Questions

Include your high-resolution CT scan showing UIP pattern, pulmonary function tests (FVC, DLCO), biopsy results if available, and documentation of any prior antifibrotic therapy and why you need an alternative.

Discuss combination therapy options with your pulmonologist. Your appeal should document why your current treatment regimen is insufficient and how Jascayd fits into your care plan.

Jascayd is a PDE4 inhibitor with a different mechanism than nintedanib or pirfenidone, potentially offering benefits for patients who cannot tolerate or do not respond to existing therapies.

Ready to Fight Your Jascayd (nerandomilast) Denial?

Our free AI-powered tool will help you generate a compelling appeal letter in minutes.

Start Your Appeal Chat with AI Assistant

Disclaimer: Fight Health Insurance is not affiliated with, endorsed by, or partnered with any pharmaceutical manufacturer, healthcare provider, medical device company, or patient assistance program, including Boehringer Ingelheim. All information provided is for educational and informational purposes only and does not constitute medical or legal advice. Please consult with your healthcare provider regarding treatment options and with your insurance company regarding coverage decisions.